Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
193 studies found for:    "Neurofibroma"
Show Display Options
Rank Status Study
1 Terminated Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas
Condition: Neurofibroma
Intervention: Drug: LS11
2 Active, not recruiting Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas
Conditions: Neurofibromatosis;   Neurofibromas
Intervention: Drug: Gleevec
3 Unknown  First Clinical Study of Erbium - Yttrium Aluminium Garnet (YAG) Laser Vaporization of Cutaneous Neurofibromas
Condition: Cutaneous Neurofibromas
Intervention: Procedure: Erbium-YAG laser vaporization
4 Completed Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1
Conditions: Neurofibromas;   Neurofibromatosis Type 1
Intervention:
5 Active, not recruiting Study of PEG-Intron for Plexiform Neurofibromas
Condition: Plexiform Neurofibroma
Intervention: Drug: PEG-Intron
6 Completed Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1
Conditions: Neurofibromatosis Type 1;   Cutaneous Neurofibromas
Intervention: Drug: Ranibizumab
7 Recruiting Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas
Condition: Plexiform Neurofibromas
Intervention: Drug: Imatinib Mesylate
8 Terminated
Has Results
Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)
Condition: Plexiform Neurofibroma Associated With Neurofibromatosis Type 1
Intervention: Drug: Everolimus (RAD001)
9 Completed
Has Results
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
Conditions: Neurofibroma, Plexiform;   Neurofibromatosis Type I
Interventions: Drug: tipifarnib;   Other: placebo
10 Completed Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1
Conditions: Neurofibromatosis Type 1;   Cutaneous Neurofibromas
Intervention: Drug: Imiquimod 5% Cream
11 Completed Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas
Conditions: Neurofibromatosis Type I;   Plexiform Neurofibroma
Interventions: Drug: Nexavar (BAY 43-9006) (Sorafenib);   Drug: Toxicity, Pharmacokinetics;   Drug: Pharmacodynamics;   Drug: Radiographic Evaluation;   Drug: QOL assessment, Neuropsychological;   Drug: Bony Toxicity
12 Completed
Has Results
Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas
Conditions: Neurofibromatosis 1;   Neurofibroma, Plexiform
Intervention: Drug: Pirfenidone
13 Recruiting Photodynamic Therapy for Benign Dermal Neurofibromas
Condition: NEUROFIBROMATOSIS 1
Intervention: Procedure: PDT Treatment
14 Completed Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1
Condition: Neurofibromatosis
Intervention: Drug: Pirfenidone
15 Recruiting Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (PNs)
Conditions: Neurofibromatosis 1;   Plexiform Neurofibromas
Intervention:
16 Recruiting Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery
Conditions: Neurofibromatosis Type 1;   Plexiform Neurofibroma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Drug: Selumetinib
17 Active, not recruiting Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)
Condition: Neurofibromatoses
Interventions: Drug: Levulan (5-aminolevulinic acid) uptake.;   Drug: Levulan (5-aminolevulinic acid) photodynamic therapy.
18 Recruiting Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain
Conditions: Neurofibromatosis Type 1;   Plexiform Neurofibromas
Intervention: Other: Acceptance and Commitment Therapy (ACT)
19 Unknown  A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas
Condition: Neurofibromatosis Type 1
Intervention: Drug: Sirolimus, Rapamycin
20 Active, not recruiting Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Conditions: Neurofibromatosis;   NF1;   Neurofibromas
Intervention: Drug: Tasigna

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.